Advances in pharmacologic agents in imaging: New A2A receptor agonists

被引：24
作者：
Cerqueira M.D. [1 ]
机构：
[1] Department of Molecular and Functional Imaging (Gb3), Cleveland Clinic Foundation, Cleveland, OH 44195
来源：
Current Cardiology Reports | 2006年 / 8卷 / 2期
关键词：
Myocardial Perfusion Imaging; Pharmacologic Stress; Regadenoson; Adenosine Receptor Subtype; Maximal Hyperemia;
D O I：
10.1007/s11886-006-0022-1
中图分类号：
学科分类号：
摘要：
Pharmacologic stress myocardial perfusion imaging is being performed with increasing frequency over exercise stress. Dipyridamole and adenosine have a high side-effect profile, provide higher than needed coronary artery flow rates, and use a relatively complicated method of administration. Based on preclinical animal work, three selective adenosine A2A receptor agonists, regadenoson (CVT3146), binodenoson (MRE047O or WRC047O), and apadenoson (BMS068645 or ATL146e), may overcome these limitations and are now in Phase III studies as pharmacologic stress agents. For single-photon emission CT imaging, binodenoson and regadenoson were concordant with adenosine images for detection and quantitation of ischemia. Despite the high A2A selectivity of binodenoson and regadenoson in preclinical studies, subjective side effects attributable to other adenosine receptor subtypes were still observed in human studies and are similar to or slightly lower than adenosine. There have been no reports of atrioventricular block or bronchospasm with either regadenoson or binodenoson in published trials. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：119 / 122
页数：3
相关论文
共 15 条
  • [1] Cerqueira M.D., Verani M.S., Schwaiger M., Et al., Safety profile of adenosine stress perfusion imaging: Results from the Adenoscan Multicenter Trial Registry, J Am Coli Cardiol, 23, pp. 384-389, (1994)
  • [2] Ranhosky A., Kempthorne-Rawson J., The safety of intravenous dipyridamole thallium myocardial perfusion imaging, Circulation, 81, pp. 1205-1209, (1990)
  • [3] Hendel R.C., Jamil T., Glover D.K., Pharmacologic stress testing: New methods and new agents, J Nucl Cardiol, 10, pp. 197-204, (2003)
  • [4] Iskandrian A.S., Verani M.S., Heo J., Pharmacologic stress testing: Mechanism of action, hemodynamic responses, and results in detection of coronary artery disease, J Nucl Cardiol, 1, pp. 94-111, (1994)
  • [5] Travain M.I., Wexler J.P., Pharmacological stress testing, Semin Nucl Med, 29, pp. 298-318, (1999)
  • [6] Cerqueira M.D., The future of pharmacologic stress: Selective A2A adenosine receptor agonists, Am J Cardiol, 94, (2004)
  • [7] Shryock J.C., Snowdy S., Baraldi P.G., Et al., A2A-adenosine receptor reserve for coronary vasodilation, Circulation, 98, pp. 711-718, (1998)
  • [8] Trochu J.N., Zhao G., Post H., Et al., Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: Potential for use in myocardial perfusion imaging, J Cardiovasc Pharmacol, 41, pp. 132-139, (2003)
  • [9] Gao Z., Li Z., Baker S.P., Et al., Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists, J Pharmacol Exp Ther, 298, pp. 209-218, (2001)
  • [10] Zhao G., Linke A., Xu X., Et al., Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs, J Pharmacol Exp Ther, 307, pp. 182-189, (2003)
12